EUVIMEDEUVIMED entdecken
Crossref

Assessment of CYP‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Yiming Cheng, Xiaomin Wang, Atalanta Ghosh, Jie Pu, Leonidas N Carayannopoulos, Yan Li

The Journal of Clinical Pharmacology · 2024

DOI: 10.1002/jcph.2436 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Yiming Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacometrics & Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA. Hauptthemen laut MEDLINE: Drug Interactions, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Midazolam. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a selective and potent inhibitor targeting the isocitrate dehydrogenase‐2 (IDH2) mutant protein, enasidenib obtained approval from the US Food and Drug Administration (FDA) in 2017 for adult patients with acute myeloid leukemia (AML) with an IDH2 mutation. In vitro investigations demonstrated that enasidenib affects various drug metabolic enzymes and transporters. This current investigation aimed to assess enasidenib on the pharmacokinetics (PKs) of CYP substrates, including dextromethorphan (CYP2D6 probe drug), flurbiprofen (CYP2C9 probe drug), midazolam (CYP3A4 probe drug), omeprazole (CYP2C19 probe drug), and pioglitazone (CYP2C8 probe drug), in patients with AML or myelodysplastic syndrome. Results showed that following the co‐administration of enasidenib (100 mg, once daily) for 28 days, the PK parameters AUC (0‐∞) and C max of dextromethorphan increased by 1.37 (90% confidence interval (CI): 0.96, 1.96) and 1.24 (90% CI: 0.94, 1.65)‐fold, respectively, compared to dextromethorphan alone. For flurbiprofen, these parameters increased by 1.14 (90%CI: 1.01, 1.29) and 0.97 (90% CI 0.86, 1.08)‐fold, respectively, when compared to flurbiprofen alone. Conversely, midazolam exhibited decreases to 0.57 (90% CI 0.34, 0.97) and 0.77 (90% CI 0.39, 1.53)‐fold, respectively, in comparison to midazolam alone. The parameters for omeprazole increased by 1.86 (90% CI: 1.33, 2.60) and 1.47 (0.93, 2.31)‐fold, respectively, compared to omeprazole alone, while those for pioglitazone decreased to 0.80 (90% CI: 0.62, 1.03) and 0.87 (90% CI: 0.65, 1.16)‐fold, respectively, in comparison to pioglitazone alone. These findings provide valuable insights into dose recommendations concerning drugs acting as substrates of CYP2D6, CYP2C9, CYP3A4, CYP2C19, and CYP2C8 when administered concurrently with enasidenib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug InteractionsLeukemia, Myeloid, AcuteMyelodysplastic SyndromesMidazolamPioglitazoneDextromethorphanPyridinesHumansMaleMiddle AgedFemaleAgedFlurbiprofenTriazinesAdultOmeprazoleCytochrome P-450 Enzyme SystemAntineoplastic AgentsRecurrenceAged, 80 and overAminopyridines

Stichwörter der Autor:innen

AMLCYP cocktailMDSdrug–drug interactionsenasidenib

Substanzen

enasidenibMidazolamPioglitazoneDextromethorphanPyridinesFlurbiprofenTriazinesOmeprazoleCytochrome P-450 Enzyme SystemAntineoplastic Agents

Autor:innen und Institutionen

  • Clinical Pharmacology, Pharmacometrics & Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA.
  • Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, NJ, USA.
  • Global Drug Development, Bristol Myers Squibb, Princeton, NJ, USA.

Förderung

  • Bristol Myers Squibb

Zitieren

APA

Cheng, Y., Wang, X., Ghosh, A., Pu, J., Carayannopoulos, L. N., & Li, Y. (2024). Assessment of CYP‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2436

Vancouver

Cheng Y, Wang X, Ghosh A, Pu J, Carayannopoulos LN, Li Y. Assessment of CYP‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2436

BibTeX
@article{Cheng2024,
  author = {Cheng, Yiming and Wang, Xiaomin and Ghosh, Atalanta and Pu, Jie and Carayannopoulos, Leonidas N and Li, Yan},
  title = {Assessment of CYP‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome},
  journal = {The Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1002/jcph.2436}
}
Kostenlos starten →